Biomarkers in active surveillance
- PMID: 29594029
- PMCID: PMC5861276
- DOI: 10.21037/tau.2017.12.26
Biomarkers in active surveillance
Abstract
The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging. In addition, monitoring protocols relying on serial biopsies is invasive and presents risks such as infection. For these reasons, there is substantial interest in identifying markers that can be used to improve AS selection and monitoring. In this article, we review the evidence on serum, urine and tissue markers in AS.
Keywords: Prostate cancer; active surveillance (AS); biomarkers; markers.
Conflict of interest statement
Conflicts of Interest: S Loeb received honoraria for lectures from Astellas, MDxHealth and Boehringer Ingelheim, reimbursed travel from Sanofi and Astellas, and consulting for GE, GenomeDx Biosciences and Lilly (unrelated to the current manuscript). JJ Tosoian has no conflicts of interest to declare.
References
-
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Available online: http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017)
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials